A personalized dosing strategy utilizing 3D printing to facilitate zolpidem withdrawal therapy

In this article, Silke Henry, Valérie Vanhoorne and Chris Vervaet, all from the Laboratory of Pharmaceutical Technology at Ghent University (Belgium), summarize the findings of their recent paper published in Pharmaceutics about utilizing 3D printing to facilitate personalized dosing solutions for zolpidem withdrawal therapy. Introduction Benzodiazepine receptor agonist (BZRA) utilization has reached worrying intake rates of 28–55% in European retirement facilities. Insomnia was the main indication for chronic BZRA utilization and lormetazepam (38%) and zolpidem (23%) were predominantly prescribed [1]. Short-acting BZRAs are mostly employed as hypnotic agents [2]. Short-term utilization of these BZRAs has shown to effectively lessen insomnia...